In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38560905.
- Also identified by DOI 10.7326/J24-0014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. <b>Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.</b> Lancet. 2024;403:271-281. 38071986.
Medical subject headings
- Anti-Asthmatic Agents
- Asthma